SANA Oct 2024 12.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 09:44AM EDT. Market open.
| Previous Close | 0.9400 |
| Open | 0.9400 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expire Date | 2024-10-18 |
| Day's Range | 0.9400 - 0.9400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireSana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “You
Simply Wall St.Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Sana Biotechnology Inc (SANA) Reports First Quarter 2024 Financial Results
Aligns with Analyst Projections Amidst Strategic Clinical Advancements
© 2024 Yahoo. All rights reserved.